Replies to post #427430 on Anavex Life Sciences Corp (AVXL)

[frrol]

It's unfortunate that a post emphasizing the limitations of animal models is necessary on a biotech board, and sad (and scary) that a HS bio teacher is the intended audience, but a thumbs up anyway.

Biotech isn't for everyone.

[falconer66a]

Anavex/Missling Have the Strong Hand

The results you cite are very good in the rat model. I would call those results highly suggestive.

And so would many others, who don't really comprehend the ubiquity of the sigma-1 receptor in all vertebrates.

However, the biologists at any of the world's major pharmaceutical manufacturers, who have scrutinized all of the published literature on Anavex 3-71, don't share your perception that the lab-confirmed data are merely "suggestive." They can see and know that blarcamesine, alone, will change CNS therapies; once commercially available. But subsequent clinical studies, in humans, will authenticate Anavex 3-71's ultimate superiority.

All of that plays into the competitive viability of both existing and proposed new CNS therapies. In two or three years, all of this will be sorted out, revealed by the profound therapeutic successes of both Anavex drugs. Missling knows the strengths of his hand in this seminal CNS drug therapy game. It will allow him to cut deals and make arrangements very favorable to both Anavex Life Sciences Corp and its stockholders.

[sab63090]

Steady T
I am certainly not qualified to speak to rat versus human, but I did see this from a very important person who did present recently:

Annovis presented three posters at the Alzheimer’s Association International Conference (AAIC) 2023 annual meeting held in Amsterdam, Netherlands, from July 16-20.

Dr. Fang presented two posters: “Do Mouse Data Lie? For Buntanetap, They Totally Predict Human Outcome,” and “Interim Analysis Results of Buntanetap in Phase III Clinical Studies in Alzheimer’s and Parkinson’s Disease.

:)